Arcturus Therapeutics (ARCT) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Arcturus Therapeutics (ARCT) has outperformed ARS Pharmaceuticals (SPRY) over the past year, losing 30.2% versus a loss of 63.5%. Over five years, SPRY leads with a -57.1% price change compared with -69.8% for ARCT. ARS Pharmaceuticals is the larger company by market cap ($420.7 million vs $390.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARCT | SPRY |
|---|---|---|
| Share price | $13.74 | $4.23 |
| Market cap | $390.53M | $420.66M |
| 1-day change | +6.76% | -7.24% |
| YTD return | +124.14% | -63.69% |
| 1-year return | -30.18% | -63.47% |
| 5-year return | -69.84% | -57.10% |
| EPS (TTM) | $-3.33 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.17 | $13.15 |
| 52-week low | $5.50 | $3.99 |
| Distance from 52-week high | -43.15% | -67.83% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +68.85% | +431.91% |
| Average volume | 939.43K | 1.86M |
| Shares outstanding | 28.42M | 99.45M |
| Employees | 106 | 195 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARCT has outperformed SPRY by 33.3 percentage points over the past year.
About Arcturus Therapeutics
ARCT stock →Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Health Care · Biotechnology: Pharmaceutical Preparations · 195 employees
ARCT vs SPRY FAQ
Which is bigger, Arcturus Therapeutics or ARS Pharmaceuticals?
ARS Pharmaceuticals (SPRY) is larger, with a market capitalization of $420.66M compared with $390.53M for Arcturus Therapeutics (ARCT).
Which stock has performed better over the past year, ARCT or SPRY?
ARCT returned -30.18% over the past 12 months, compared with -63.47% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Are Arcturus Therapeutics and ARS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.